| Literature DB >> 3861233 |
K Kimura, R Ohno, I Amaki, K Hattori, Y Hirota, A Hoshino, M Ichimaru, M Ito, I Kimura, T Maekawa.
Abstract
Forty-five previously-untreated adult patients with acute myelogenous leukemia (AML) were treated with N4-behenoyl-1-beta-D-arabinofuranosyl-cytosine (BHAC) in a multi-institutional cooperative study. Among 41 evaluable patients, 15 (36.6%) achieved complete remission (CR) and 10 (24.4%) achieved partial remission by daily administration of 3 to 8 mg/kg of BHAC. Higher daily doses (5 mg/kg or more) produced higher CR rates, and all of the CR were observed among the patients receiving a total BHAC dosage of 50 mg/kg or more in a period of 10 days or more. The side effects were mild and acceptable: nausea-anorexia was observed in 27% of the patients and vomiting in 17%. The results of this study thus indicate BHAC to be effective for remission induction of AML, and to deserve further clinical trials in combination with other anti-leukemic drugs.Entities:
Mesh：
Substances：
Year: 1985 PMID： 3861233 DOI： 10.1002/1097-0142(19851015)56:8<1913::aid-cncr2820560803>3.0.co;2-w
Source DB: PubMed Journal: Cancer ISSN： 0008-543X Impact factor: 6.860